KALA Share Price

KALA Share Price

NASDAQ: KALA | Micro Cap | Healthcare
$3.31
+$3.31 (--%) Last updated on 19 Nov, 2026 | 01:59 IST
  • Performance
  • Chart
  • Fundamentals
  • Profit & Loss
  • Balance Sheet
  • Cash Flow
  • Corporate Actions
  • About
  • Price history
  • FAQs

KALA Stock Performance

Open
N/A
Prev. Close
N/A
Circuit Range
N/A
Day Range
N/A
Year Range
$0.07 - $3.90
Volume
N/A
Average Traded
N/A

KALA Share Price Chart

Line chart of the KALA price trend over the selected period. The price rose overall, ranging from 3.31 to 3.48, ending at 3.31.
$0.00$0.00
L
Show Current Price
H

KALA Stock Fundamentals & Key Indicators

Market Cap
$26.97M
PE Ratio (TTM)
N/A
Dividend Yield
0.00%
EPS (TTM)
$-15.64
Revenue (TTM)
$0.00
Return On Equity (TTM)
-111.46%
Profit Margin
N/A
Debt to Equity
0.00
Quarterly Earnings Growth YoY
79.10%

KALA Quarterly Profit & Loss

All figures in USD

ParticularsSep 2025Dec 2025Mar 2026Jun 2026
Revenue$0.00$0.00$0.00$0.00
Net Profit-$7.56$0.69-$1.62-$1.58
Net Profit MarginN/AN/AN/AN/A
Income ChangeN/A109.13%-334.78%2.47%

KALA Annual Profit & Loss

All figures in USD

Particulars2022202320242025
Revenue$3.89$0.00$0.00$0.00
Net Profit-$44.82-$42.20-$38.51-$26.98
Net Profit Margin-1152.19%N/AN/AN/A
Income ChangeN/A5.85%8.74%29.94%

KALA Balance Sheet

All figures in USD Million

Particulars2025202420232022
Non Current Assets0.02.693.080.88
Current Assets9.4952.852.8785.94
Total Assets9.4955.4855.9586.82
Non Current Liabilities0.026.240.142.16
Current Liabilities2.4916.968.3525.69
Total Liabilities2.4943.1548.4567.85
Shareholders' Equity7.012.337.518.97

KALA Cash Flow

Annually

All figures in USD Million

Particulars2025202420232022
Operating-31.99-29.38-27.93-78.91
Investing-0.02-0.21-0.4362.72
Financing-11.6229.888.51-7.94

Corporate Actions

Split
Ex-date: 16 Nov 2026

Split
Ex-date: 11 May 2026

Split
Ex-date: 21 Oct 2022

Split
Ex-date: 26 Aug 2022

About KALA

Kala Bio Inc is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of inventive therapies for rare and severe diseases of the front and back of the eye. It main product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.

KALA Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Nov 2026
$0.18
$0.14
-19.53%
Oct 2026
$0.43
$0.17
-60.51%
Sep 2026
$0.52
$0.43
-47.29%
Aug 2026
$0.76
$0.81
+3.18%
Jul 2026
$1.80
$0.79
-54.64%
Jun 2026
$2.29
$1.74
-22.20%
May 2026
$0.11
$2.23
+2,023.81%
Apr 2026
$0.19
$0.10
-39.66%
Mar 2026
$0.38
$0.17
-54.57%
Feb 2026
$0.52
$0.38
-26.49%
Jan 2026
$0.58
$0.52
-5.96%
Dec 2025
$1.29
$0.55
-41.93%

KALA Share Price FAQs